Novartis (NYSE:NVS) is set to post its quarterly earnings results before the market opens on Thursday, October 18th. Analysts expect Novartis to post earnings of $1.34 per share for the quarter.
Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, July 18th. The company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.02. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The company had revenue of $13.16 billion during the quarter, compared to analyst estimates of $12.93 billion. During the same period in the previous year, the business earned $1.22 EPS. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts expect Novartis to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.
Shares of NYSE NVS opened at $83.15 on Tuesday. Novartis has a twelve month low of $72.30 and a twelve month high of $94.19. The company has a market capitalization of $199.67 billion, a P/E ratio of 17.29, a PEG ratio of 1.80 and a beta of 0.83. The company has a quick ratio of 0.89, a current ratio of 1.15 and a debt-to-equity ratio of 0.30.
A number of equities research analysts have weighed in on the stock. ValuEngine lowered shares of Novartis from a “sell” rating to a “strong sell” rating in a research note on Monday, July 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research note on Thursday, October 11th. Goldman Sachs Group reiterated a “neutral” rating on shares of Novartis in a research note on Wednesday, October 10th. DZ Bank reiterated a “buy” rating on shares of Novartis in a research note on Thursday, July 19th. Finally, Zacks Investment Research upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research note on Tuesday, June 19th. Thirteen analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $86.90.
In related news, major shareholder Bioventures Ltd Novartis sold 8,181 shares of the company’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $3.22, for a total value of $26,342.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 81,022 shares of company stock valued at $289,251 in the last ninety days. 0.01% of the stock is currently owned by insiders.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.